CD19-CD22 CAR-T cells is under clinical development by Shanghai Biomed-Union Biotechnology and currently in Phase II for Unspecified B-Cell Lymphomas.

The therapeutic candidate is under development for the treatment of ovarian cancer. It comprises of induced pluripotent stem (iPS) cell derived natural killer (iNK) cell.

COVID-19 (omicron JN.1) vaccine is under clinical development by Moderna and currently in Pre-Registration for Coronavirus Disease 2019 (COVID-19).

NUV-868 is under clinical development by Nuvation Bio and currently in Phase II for Triple-Negative Breast Cancer (TNBC).

BM-219 is under clinical development by Suzhou Biomissile Biopharmaceutical and currently in Phase I for Coronavirus Disease 2019 (COVID-19).

NA-731 is under clinical development by Biomed Industries and currently in Phase I for Traumatic Brain Injury.

LR-19155 is under clinical development by LG Chem and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 80% phase ...

Anti-CDH17 CAR-T Cells is under clinical development by UTC Therapeutics and currently in Phase I for Pancreatic Cancer.

TCA-101 is under clinical development by TCR Cure Biopharma Technology and currently in Phase II for Solid Tumor.

MET-3 is under development for the treatment of hypertriglyceridemia. It comprises live microbiota that normally reside in the human gut of a healthy individual. It is administered through oral route ...

VI-0810 is under development for the treatment of diabetes. Vivus, a subsidiary of Icahn Enterprises LP, is developing drugs for the treatment of exocrine pancreatic insufficiency, obesity and ...